RNA interference versus antibody-based PCSK9 inhibition for the prevention of cardiovascular disease: A drug-target Mendelian randomization study
{{output}}
Aims: RNA interference therapies targeting liver expression of the gene proprotein convertase subtilisin/kexin type 9 (PCSK9) lower low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB) levels. As opposed to mon... ...
